Rheumatoid arthritis: Pathogenesis and early recognition

American Journal of Medicine

Volumn 100, Issue 2 A, 1996, Pages 3S-9S

  Pope, Richard M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; ANTIRHEUMATIC AGENT;

ARTHRALGIA; CONFERENCE PAPER; CONSERVATIVE TREATMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DISEASE SEVERITY; EARLY DIAGNOSIS; HUMAN; JOINT DESTRUCTION; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; RHEUMATOID ARTHRITIS; TREATMENT PLANNING; ADULT; ARTHROGRAPHY; CASE REPORT; FEMALE; JOINT; PATHOLOGY; REVIEW; RISK FACTOR; TIME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; FEMALE; HUMANS; JOINTS; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 84975705764     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(97)89540-x     Document Type: Conference Paper

References (53)

1. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
2. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Eng J Med. 1990;322:1277-1289.
3. Yelin E, Henke C, Epstein E. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum. 1988;30:348-357.
4. Mitchell JM, Burkhauser RV, Pincus T. The importance of age, education and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis. Arthritis Rheum. 1988;31:348-357.
5. Mutru O, Laakso M, Isomaki H, Koota K. Ten-year mortality and causes of death in patients with rheumatoid arthritis. Br Med J. 1985;290:1797-1799.
6. Mitchell DM, Spitz PW, Young DY, et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum, 1986;29:706-714.
7. Pincus T, Callahan LF, Vaughn WK. Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol. 1987;14:240-251.
8. Katz WA. Rheumatoid arthritis - management. In: Katz WA, ed. Diagnosis and Management of Rheumatic Disease, 2nd ed. Philadelphia: JB Lippincott, 1980:380-395.
9. Fries JG. Reevaluating the therapeutic approach to rheumatoid arthritis: the saw-tooth strategy. J Rheumatol. 1990;17(suppl 22):12-15.
10. Davis MJ, Dawes PT, Fowler PD, et al. Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol. 1991;30:451-454.
11. Schumacher HR Jr, Bautista BB, Krauser RE, Mathur AK, Gall EP. Histological appearance of the synovium in early rheumatoid arthritis. Semin Arthritis Rheum. 1994;23(suppl 2):3-10.
12. Chan KA, Felson DT, Yood RA, Walker AM. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum. 1994;37:814-820.
13. Soden M, Rooney M, Cullen A, et al. Immunohistological features in the synovium obtained from clinically uninvolved knee joints of patients with rheumatoid arthritis. Br J Rheumatol. 1989;28:287-292.
14. Zvaifler NJ, Boyle D, Firestein GS. Early synovitis - synoviocytes and mononuclear cells. Semin Arthritis Rheum. 1994;23(suppl 2):11-16.
15. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am. 1993;19:123-151.
16. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arthritis Rheum. 1986;29:494-500.
17. Forslind K, Eberhardt K, Jonsson A, Saxne T. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol. 1992;31:593-598.
18. Mansson B, Carey D, Alini M, et al. Cartilage and bone metabolism in rheumatoid arthritis. J Clin invest 1995;95:1071-1077.
19. McDermott M, McDevitt H. The immunogenetics of rheumatic diseases. Bull Rheum Dis. 1988;38:1-10.
20. Stastny P. Association of B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med. 1978;298:869-871.
21. Calm A, Elswood J, Klouda PT. Destructive arthritis, rheumatoid factor, and HLA-DR4. Susceptibility versus severity, a case-control study. Arthritis Rheum. 1989;32:1221-1225.
22. Weyand C, Hicock K, Conn DL, Goronzy JJ. The influence of HLA-DrB1 genes on disease activity in rheumatoid arthritis. Ann Intern Med. 1992;117:801-806.
23. Ianuzzi L, Dawson N, Zein N, et al. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med. 1983;309:1023-1028.
24. Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum. 1994;37:1492-1498.
25. Wilske KR, Healey LA. Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis. J Rheumatol. 1990;17(suppl 25):4-7.
26. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med. 1995;333:137-141.
27. Liang GC, Pope RM, Lessand J. Addition of sulfasalazine to rheumatoid arthritis patients inadequately controlled with methotrexate. (Abstr.) Arthritis Rheum. 1995;38(suppl):S367.
28. Stastny P. Mixed lymphocyte culture typing cells from patients with rheumatoid arthritis. Tissue Antigen. 1974;4:571-579.
29. Karr RW, Rodey GE, See T, et al. Association of HLA-DRw4 with rheumatoid arthritis in black and white patients. Arthritis Rheum. 1980;23:1241-1245.
30. Ohta N, Nishimura YK, Tanimoto K, et al. Association between HLA and Japanese patients with rheumatoid arthritis. Hum Immunol. 1982;5:123-132.
31. Gorodezky C, Lavalle C, Castro-Escobar LE, et al. HLA antigens in Mexican patients with rheumatoid arthritis. (Letter.) Arthritis Rheum. 1980;24:976-977.
32. Woodrow JC, Nichol FE, Zaphiropoulos G. DR antigens and rheumatoid arthritis: a study of two populations. Br Med J. 1981;283:1287-1288.
33. Schiff B, Mizrachi Y, Orgad S, Yaron M, Gazit E. Association of HLA-Aw31 and HLA-Dr1 with adult rheumatoid arthritis. Ann Rheum Dis. 1982;41:403-404.
34. Brauthar C, Naparstek Y, Yaron M, et al. Immunogenetics of rheumatoid arthritis in Israel. Tissue Antigens. 1986;28:8-14.
35. Willkens RF, Hansen JA, Malmgren JA, et al. HLA antigens in Yakima Indians with rheumatoid arthritis. Arthritis Rheum. 1982;25:1435-1439.
36. Sigler JW, Bluhm GB, Duncan H, et al. Gold salts in the treatment of rheumatoid arthritis: a double-blind study. Ann Intern Med. 1974;80:21-26.
37. Cooperating Clinics Committee of the American Rheumatism Association. A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum, 1973;16:353-358.
38. Luukkainen R. Chrysotherapy in rheumatoid arthritis: with particular emphasis on the effect of chrysotherapy on radiographical changes and on the optimal time of initiation of therapy. Scand J Rheumatol. 1980;34(suppl):1-56.
39. Ellman P, Lawrence JS, Thorold GP. Gold therapy in rheumatoid arthritis. Br Med J. 1940;2:314-316.
40. Research Sub-committee of the Empire Rheumatism Council. Gold therapy in rheumatoid arthritis: report of a multi-centre controlled trial. Ann Rheum Dis. 1960;19:95-119.
41. Research Sub-committee of the Empire Rheumatism Council. Gold therapy in rheumatoid arthritis: final report of a multicenter controlled trial. Ann Rheum Dis. 1961;20:315-334.
42. Multicentre Trial Group. Controlled trial of D(-)penicillamine in severe rheumatoid arthritis. Lancet. 1973;i:275-280.
43. Shiokawa Y, Horiuchi Y, Honma M, et al. Clinical evaluation of D-penicillamine by multicentric double-blind comparative study in chronic rheumatoid arthritis. Arthritis Rheum. 1977;20:1464-1472.
44. Dixon AS, Davies J, Dormandy TL, et al. Synthetic D(-)penicillamine in rheumatoid arthritis: double-blind controlled study of a high and low dosage regimen. Ann Rheum Dis. 1975;34:416-421.
45. Freedman A, Steinberg VL. Chloroquine in rheumatoid arthritis: a double blindfold trial of treatment for one year. Ann Rheum Dis. 1960;19:243-250.
46. Popert AJ, Meijers KAE, Sharp J, Bier F. Chloroquine diphosphate in rheumatoid arthritis: a controlled trial. Ann Rheum Dis. 1961;20:18-35.
47. Mainland D, Sutcliffe MI. Hydroxychloroquine sulfate in rheumatoid arthritis: a six month, double-blind trial. Bull Rheum Dis. 1962;13:287-290.
48. Hamilton EB, Scott JT. Hydroxychloroquine sulfate ("Plaquenil") in treatment of rheumatoid arthritis. Arthritis Rheum. 1962;5:502-512.
49. Urowitz MB, Gordon DA, Smythe HA, Pruzanski W, Ogryzlo MA. Azathioprine in rheumatoid arthritis: a double-blind, cross-over study. Arthritis Rheum. 1973;16:411-418.
50. Cooperating Clinics Committee of the American Rheumatoid Association. A controlled trial of cyclophosphamide in rheumatoid arthritis. N Engl J Med. 1970;283:883-889.
51. Lidsky MD, Sharp JT, Billings S. Double-blind study of cyclophosphamide in rheumatoid arthritis. Arthritis Rheum. 1973;16:148-153.
52. Townes AS, Sowa JM, Shulman LE. Controlled trial of cyclophosphamide in rheumatoid arthritis. Arthritis Rheum. 1976;19:563-573.
53. Smyth CJ, Bartholomew BA, Mills DM, et al. Cyclophosphamide therapy for rheumatoid arthritis. Arch Intern Med. 1975;135:789-793.